Supply chain imperatives are evolving from drug production and delivery that are limited in scope towards a versatile supply chain addressing the needs of multiple stakeholders (such as caregivers, patients and insurance companies). The traditional supply chain approach based on materials requirement planning has progressed to its limits. From the patient perspective, the current supply chain creates frustration and complications in individualized treatments, or even fails to offer satisfactory performance with new treatment types (for example, companion diagnostic, individualized dosage, combination therapies). From an industrial perspective, as new treatments become available, new types of supply chains need to be established, with new actors, as well as new technological and logistical systems. In this article, Marc Herlant, Partner at Arthur D. Little, discusses the intelligent supply chain.